Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company dedicated to the formulation, development, and commercialization of innovative therapies for eye diseases and conditions. Utilizing its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™, the company aims to simplify the current standard of care and establish itself as a leader in the ophthalmic sector. Based in Bedford, MA, Ocular Therapeutix fosters a strong workplace culture that encourages creativity, cross-functional collaboration, and employee growth.